Hematopoietic Stem Cell Transplantation Market Size to Hit USD 24.32 Billion by 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Hematopoietic Stem Cell Transplantation Market

5.1. COVID-19 Landscape: Hematopoietic Stem Cell Transplantation Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Hematopoietic Stem Cell Transplantation Market, By Type of Transplant

8.1. Hematopoietic Stem Cell Transplantation Market, by Type of Transplant

8.1.1. Autologous Stem Cell Transplantation (ASCT)

8.1.1.1. Market Revenue and Forecast

8.1.2. Allogeneic Stem Cell Transplantation (AlloSCT)

8.1.2.1. Market Revenue and Forecast

8.1.3. Syngeneic Stem Cell Transplantation

8.1.3.1. Market Revenue and Forecast

Chapter 9. Global Hematopoietic Stem Cell Transplantation Market, By Stem Cell Source

9.1. Hematopoietic Stem Cell Transplantation Market, by Stem Cell Source

9.1.1. Bone Marrow-derived Stem Cells

9.1.1.1. Market Revenue and Forecast

9.1.2. Peripheral Blood Stem Cells

9.1.2.1. Market Revenue and Forecast

9.1.3. Umbilical Cord Blood Stem Cells

9.1.3.1. Market Revenue and Forecast

Chapter 10. Global Hematopoietic Stem Cell Transplantation Market, By Conditioning Regimen

10.1. Hematopoietic Stem Cell Transplantation Market, by Conditioning Regimen

10.1.1. Myeloablative Conditioning

10.1.1.1. Market Revenue and Forecast

10.1.2. Non-myeloablative Conditioning

10.1.2.1. Market Revenue and Forecast

10.1.3. Reduced Intensity Conditioning

10.1.3.1. Market Revenue and Forecast

Chapter 11. Global Hematopoietic Stem Cell Transplantation Market, By Application

11.1. Hematopoietic Stem Cell Transplantation Market, by Application

11.1.1. Hematologic Malignancies

11.1.1.1. Market Revenue and Forecast

11.1.2. Non-malignant Hematological Disorders

11.1.2.1. Market Revenue and Forecast

11.1.3. Autoimmune Diseases

11.1.3.1. Market Revenue and Forecast

11.1.4. Genetic Disorders

11.1.4.1. Market Revenue and Forecast

Chapter 12. Global Hematopoietic Stem Cell Transplantation Market, By End-Use

12.1. Hematopoietic Stem Cell Transplantation Market, by End-Use

12.1.1. Hospitals

12.1.1.1. Market Revenue and Forecast

12.1.2. Specialized Hematopoietic Transplant Centers

12.1.2.1. Market Revenue and Forecast

12.1.3. Research Institutes

12.1.3.1. Market Revenue and Forecast

12.1.4. Homecare

12.1.4.1. Market Revenue and Forecast

Chapter 13. Global Hematopoietic Stem Cell Transplantation Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Type of Transplant

13.1.2. Market Revenue and Forecast, by Stem Cell Source

13.1.3. Market Revenue and Forecast, by Conditioning Regimen

13.1.4. Market Revenue and Forecast, by Application

13.1.5. Market Revenue and Forecast, by End-Use

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Type of Transplant

13.1.6.2. Market Revenue and Forecast, by Stem Cell Source

13.1.6.3. Market Revenue and Forecast, by Conditioning Regimen

13.1.6.4. Market Revenue and Forecast, by Application

13.1.6.5. Market Revenue and Forecast, by End-Use

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Type of Transplant

13.1.7.2. Market Revenue and Forecast, by Stem Cell Source

13.1.7.3. Market Revenue and Forecast, by Conditioning Regimen

13.1.7.4. Market Revenue and Forecast, by Application

13.1.7.5. Market Revenue and Forecast, by End-Use

13.2. Europe

13.2.1. Market Revenue and Forecast, by Type of Transplant

13.2.2. Market Revenue and Forecast, by Stem Cell Source

13.2.3. Market Revenue and Forecast, by Conditioning Regimen

13.2.4. Market Revenue and Forecast, by Application

13.2.5. Market Revenue and Forecast, by End-Use

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Type of Transplant

13.2.6.2. Market Revenue and Forecast, by Stem Cell Source

13.2.6.3. Market Revenue and Forecast, by Conditioning Regimen

13.2.7. Market Revenue and Forecast, by Application

13.2.8. Market Revenue and Forecast, by End-Use

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Type of Transplant

13.2.9.2. Market Revenue and Forecast, by Stem Cell Source

13.2.9.3. Market Revenue and Forecast, by Conditioning Regimen

13.2.10. Market Revenue and Forecast, by Application

13.2.11. Market Revenue and Forecast, by End-Use

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Type of Transplant

13.2.12.2. Market Revenue and Forecast, by Stem Cell Source

13.2.12.3. Market Revenue and Forecast, by Conditioning Regimen

13.2.12.4. Market Revenue and Forecast, by Application

13.2.13. Market Revenue and Forecast, by End-Use

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Type of Transplant

13.2.14.2. Market Revenue and Forecast, by Stem Cell Source

13.2.14.3. Market Revenue and Forecast, by Conditioning Regimen

13.2.14.4. Market Revenue and Forecast, by Application

13.2.15. Market Revenue and Forecast, by End-Use

13.3. APAC

13.3.1. Market Revenue and Forecast, by Type of Transplant

13.3.2. Market Revenue and Forecast, by Stem Cell Source

13.3.3. Market Revenue and Forecast, by Conditioning Regimen

13.3.4. Market Revenue and Forecast, by Application

13.3.5. Market Revenue and Forecast, by End-Use

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Type of Transplant

13.3.6.2. Market Revenue and Forecast, by Stem Cell Source

13.3.6.3. Market Revenue and Forecast, by Conditioning Regimen

13.3.6.4. Market Revenue and Forecast, by Application

13.3.7. Market Revenue and Forecast, by End-Use

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Type of Transplant

13.3.8.2. Market Revenue and Forecast, by Stem Cell Source

13.3.8.3. Market Revenue and Forecast, by Conditioning Regimen

13.3.8.4. Market Revenue and Forecast, by Application

13.3.9. Market Revenue and Forecast, by End-Use

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Type of Transplant

13.3.10.2. Market Revenue and Forecast, by Stem Cell Source

13.3.10.3. Market Revenue and Forecast, by Conditioning Regimen

13.3.10.4. Market Revenue and Forecast, by Application

13.3.10.5. Market Revenue and Forecast, by End-Use

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Type of Transplant

13.3.11.2. Market Revenue and Forecast, by Stem Cell Source

13.3.11.3. Market Revenue and Forecast, by Conditioning Regimen

13.3.11.4. Market Revenue and Forecast, by Application

13.3.11.5. Market Revenue and Forecast, by End-Use

13.4. MEA

13.4.1. Market Revenue and Forecast, by Type of Transplant

13.4.2. Market Revenue and Forecast, by Stem Cell Source

13.4.3. Market Revenue and Forecast, by Conditioning Regimen

13.4.4. Market Revenue and Forecast, by Application

13.4.5. Market Revenue and Forecast, by End-Use

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Type of Transplant

13.4.6.2. Market Revenue and Forecast, by Stem Cell Source

13.4.6.3. Market Revenue and Forecast, by Conditioning Regimen

13.4.6.4. Market Revenue and Forecast, by Application

13.4.7. Market Revenue and Forecast, by End-Use

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Type of Transplant

13.4.8.2. Market Revenue and Forecast, by Stem Cell Source

13.4.8.3. Market Revenue and Forecast, by Conditioning Regimen

13.4.8.4. Market Revenue and Forecast, by Application

13.4.9. Market Revenue and Forecast, by End-Use

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Type of Transplant

13.4.10.2. Market Revenue and Forecast, by Stem Cell Source

13.4.10.3. Market Revenue and Forecast, by Conditioning Regimen

13.4.10.4. Market Revenue and Forecast, by Application

13.4.10.5. Market Revenue and Forecast, by End-Use

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Type of Transplant

13.4.11.2. Market Revenue and Forecast, by Stem Cell Source

13.4.11.3. Market Revenue and Forecast, by Conditioning Regimen

13.4.11.4. Market Revenue and Forecast, by Application

13.4.11.5. Market Revenue and Forecast, by End-Use

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Type of Transplant

13.5.2. Market Revenue and Forecast, by Stem Cell Source

13.5.3. Market Revenue and Forecast, by Conditioning Regimen

13.5.4. Market Revenue and Forecast, by Application

13.5.5. Market Revenue and Forecast, by End-Use

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Type of Transplant

13.5.6.2. Market Revenue and Forecast, by Stem Cell Source

13.5.6.3. Market Revenue and Forecast, by Conditioning Regimen

13.5.6.4. Market Revenue and Forecast, by Application

13.5.7. Market Revenue and Forecast, by End-Use

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Type of Transplant

13.5.8.2. Market Revenue and Forecast, by Stem Cell Source

13.5.8.3. Market Revenue and Forecast, by Conditioning Regimen

13.5.8.4. Market Revenue and Forecast, by Application

13.5.8.5. Market Revenue and Forecast, by End-Use

Chapter 14. Company Profiles

14.1. Novartis

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Gilead Sciences

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Baxter International

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Fresenius Kabi

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Celgene (Bristol Myers Squibb)

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Medtronic

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Amgen

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Miltenyi Biotec

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. AllCells

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Thermo Fisher Scientific

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at [email protected]

Frequently Asked Questions

Answer : The hematopoietic stem cell transplantation market size is expected to increase from USD 11.80 billion in 2025 to USD 24.32 billion by 2035.

Answer : The hematopoietic stem cell transplantation market is expected to grow at a compound annual growth rate (CAGR) of around 7.50% from 2026 to 2035.

Answer : The major players in the hematopoietic stem cell transplantation market include Novartis, Gilead Sciences, Baxter International, Fresenius Kabi, Celgene (Bristol Myers Squibb), Medtronic, Amgen, Miltenyi Biotec, AllCells, Thermo Fisher Scientific, Hematologic Technologies, Bio-Rad Laboratories, Takeda Pharmaceutical Company, Sandoz (Novartis), and Oasis Diagnostics.

Answer : The driving factors of the hematopoietic stem cell transplantation market are the rising incidence of blood cancers and advancements in stem cell transplant technologies drive the market.

Answer : North America region will lead the global hematopoietic stem cell transplantation market during the forecast period 2026 to 2035.